Multi-dimensional omics could be helpful to interpret the underlying mechanisms of disease. Severe sepsis (SS) is a major cause of mortality and morbidity in intensive care units and has a large burden on healthcare due to a lack of effective drugs. The underlying pathophysiology of SS is also poorly understood. A huaxian capsule (HXC) is a herbal preparation with putative effects for SS treatment. Here, we aimed to investigate the metabolic changes in SS rats by performing metabolic profiling and biomarker analysis. The phenotypic response was assessed by UPLC/MS combined with chemometrics. As a result, 12 potential metabolite biomarkers were identified and involved in multiple dysregulated metabolic pathways, such as glycerophospholipid metabolism, steroid hormone biosynthesis, and disrupted sphingolipid metabolism, etc. Then, we performed microRNA analysis to reveal that the HXC ameliorates the dysregulated expression profiling of SS. We identified 56 miRNAs that were differentially expressed in the HXC group compared with the model group, of which 20 were down-regulated and 36 were up-regulated. This study showed that microRNA and metabolic profiling is a valuable approach for exploring metabolism responses to herbal drugs, and can improve our understanding of the molecular basis of the SS treatment.
Introduction
Metabolomics, the global assessment of endogenous small molecule metabolites in a biological sample, provides a powerful platform for identifying biomarkers to improve the treatment of disease, 1,2 identify perturbed pathways, 3, 4 and discover new drugs. 5 By analyzing and verifying the signicant difference in metabolic proles and changes of metabolite biomarkers, metabolomics enables us to better understand metabolic pathways that can clarify the mechanism of traditional Chinese medicines (TCM). [6] [7] [8] [9] It enables us to better understand substance metabolic pathways which can explain the mechanism of action, and has been successfully used in various elds of TCM research. [10] [11] [12] Ultra performance liquid chromatography coupled with quadrupole time-of-ight mass spectrometry (UPLC-Q-TOF/MS) technique has been widely used for metabolomic analysis in TCM. 13 Severe sepsis (SS) has been considered a life-threatening clinical syndrome throughout the world.
14-16 Also, there is an urgent need for reliable biomarkers for therapeutically evaluation of the SS disease. Despite recent advances in antibiotic therapies, sepsis remains a leading cause of morbidity and mortality in critically ill patients. 17 TCM has been used as a regular treatment for many diseases in many Asian countries. 18 Metabolomics has become an important tool for assessing the effects of herbs and TCM formulae. 19 Huaxian capsule (HXC), TCM formulae, has been widely used for the clinical treatment of SS for many years. 20 Comprehensive mechanisms of the pharmacological effects of HXC remain to be elucidated. miRNAs are endogenous non-coding singlestranded RNA molecules made of approximately 22 nucleotides. They can play an important role in the regulation of metabolic prole. Recent studies highlight the use of new miRNAs biomarkers for sepsis. The differential expression of miRNAs in the pathogenesis of sepsis including miR-150, miR133a, miR-122, miR-223, miR-4772, miR-297 and miR-574-5p, etc., [21] [22] [23] [24] [25] can be used as biomarkers for the diagnosis and prognosis of sepsis. Zhou et al. had showed that the upregulation of MicroRNA-205-5b as a potential therapeutic target for the treatment of sepsis.
26 Some evidence recently showed that the abnormal expression of miRNA is closely related with the occurrence and development of diseases. Therefore, the present study using high-throughput microRNA and metabolome expression proling method was conducted to investigate the metabolic mechanisms of HXC exerting its therapeutic effect in a model of SS.
Materials and methods

Chemicals and reagents
Acetonitrile and methanol (HPLC grade) were purchased from Fisher Corporation (Loughborough, UK); water was produced by a Milli-Q Ultra-pure water system (Millipore, USA); formic acid was obtained from Honeywell Company (Morristown, USA); leucine enkephalin was purchased from Sigma-Aldrich (St. Louis, USA). All other reagents were HPLC grade. HXC was a clinical preparation and obtained from First Affiliated Hospital, Heilongjiang University of Chinese Medicine.
Animal
Adult male Wistar rats (weighting 220 AE 20 g) were purchased from the SLAC Laboratory Animal Co. (Shanghai, China). Rats were kept in SPF-grade Experimental Animal Houses of Heilongjiang University of Chinese Medicine (Harbin, China) with free access to food and water under standard temperature conditions at 24 AE 2 C with 40 AE 5% humidity and a 12 h light/ dark cycle. The experimental procedures were approved by the Animal Care and Ethics Committee at Heilongjiang University of Chinese Medicine (approval number: HUCM2015-0602).
Sepsis model
The cecal ligation and puncture (CLP) method was used as a SS model, as described in the literature. 27 Under ether anesthesia, a midline incision (approximately 2 cm) was made and the cecum was divided carefully while avoiding all blood vessels. The distal two thirds of the cecum was punctured through twice with an 18-gauge needle and ligated tightly. Then, the cecum was placed back in the peritoneal cavity, and the abdominal cavity was closed. In sham surgical controls, the cecum was exposed but not punctured and ligated before being returned to the abdominal cavity. The animals were allowed to acclimatize and putted in the metabolism cages.
Sample collection
The rats were randomly divided into model group (n ¼ 8, treated with 0.2 mL solution immediately and 24 hours aer CLP), HXC treatment group (n ¼ 8, orally administered at a dose of 2 g kg À1 of body weight once a day and 24 hours aer CLP), and sham (control) group (n ¼ 8, treated with shame operation and the same volume of 0.9% saline solution). Drug or vehicle was administrated between 8:00 and 9:00 am to minimize any effects of the circadian rhythm. Aer 3 consecutive days of drug administration, all of the animals were sacriced by exsanguination from the abdominal aorta under isourane anesthesia. The blood was collected in heparinized tubes and centrifuged at 10 000 rpm for 10 min at 4 C. Then, the plasma was obtained and stored at À80 C for analysis.
Sample preparation and pretreatment
Prior to analysis, plasma samples were thawed at room temperature for 15 min, vortexed vigorously for 10 s, and then 200 mL of methanol was added to 100 mL of the plasma samples and vortexed vigorously for 20 s, in order to extract the metabolites. The sample mixture was allowed to stand for 10 min at 4 C and centrifuged at 10 000 rpm for 10 min at 4 C. The supernatant (100 mL) was transferred to afresh tube then evaporated to dryness by nitrogen blowing, then 200 mL of 80% methanol were added and vortex-mixed. The supernatant was then transferred to a auto-sampler injection vial for UPLC/MS analysis. To ensure the analytical variability and to monitor the data acquisition performance in the whole run, pooled quality control (QC) samples were prepared from 10 mL of each sample.
2.6 UPLC-QTOF/MS analysis 2.6.1 UPLC. The UPLC analysis was performed on a Waters ACQUITY UPLC system (Waters Corporation, Milford, MA). An Acquity UPLC BEH-C 18 column (2.1 mm Â 100 mm Â 1.8 mm) was used for all analyses. The column was maintained at 40 C, and a gradient of 0.1% formic acid in water (solvent A) and acetonitrile (solvent B) was used. The gradient used for plasma samples was as follows: 2.0-25% B over 0-4.0 min; 25-80% B over 4.0-6.0 min; and 80% for 6.0-10 min, 90% for 10-11 min, aer which it was returned to 2% B for 1.0 min. The ow rate was set to 0.3 mL min
À1
, and a 4 mL aliquot of the sample solution was injected into the system. The samples were maintained at 4 C during the analysis.
Mass spectrometry.
Mass spectrometry was performed on a Q-TOF mass spectrometer (Waters, Manchester, U.K.). UHPLC-QTOF-MS was used for the relative quantication analysis of potential biomarkers. The parameters in the source were set as follows: capillary voltage, 2.0 kV; source temperature, 110 C; desolvation temperature, 500 C; cone gas ow, 60 L h À1 ; and desolvation gas ow, 400 L h À1 . Centroid data were collected from 50 to 1000 m/z with a scan time of 0.03 s, and an interscan delay of 0.02 s. Data were processed further using MassLynx 4.1 (Waters, Manchester, U.K.). Leucineenkephalin was used as the lock mass (m/z 556.2771 in ES + and 554.2615 in ES À ).
2.6.3 Data processing and multivariate data analysis. All the data for plasma was processed using MassLynx V4.1 and MarkerLynx soware (Waters Corp., Milford, MA). Ion intensity was normalized with respect to the total ion count to generate a data matrix including the retention time, m/z value, and the normalized peak area. The mass data acquired were analyzed using EZinfo 2.0 soware (Waters Corp, Milford, USA) for peak detection and alignment. EZinfo 2.0 soware was then used to perform unsupervised principal components analysis (PCA) and partial least squares projection to supervised latent structures and discriminant analysis (PLS-DA) and orthogonal partial least-squared discriminate analysis (OPLS-DA). PCA was used to convert multiple original variable spaces into a new set of orthogonal variables, and were employed to reveal the global metabolic changes. PLS-DA and OPLS-DA were applied to determine the various metabolites responsible for the separation between the model and shamoperated groups. The corresponding variable importance in the projection (VIP values) was calculated in the OPLS-DA model as well, a weighted sum of squares, was used to select biomarkers.
2.6.4 Identication of plasma biomarkers. For the identication of potential biomarkers, some available biochemical databases, such as Chemspider, HMDB, KEGG, METLIN, and LIPIDMAPS were used by comparing the accurate mass, fragments information and MS/MS data. Moreover, the potential biomarkers among them were further identied by comparing with reference standards.
2.6. 
microRNA expression analysis
Total RNA was isolated from serum by Trizol method according to the previous method. Serum RNA samples were subjected to miRNA proling using a TaqMan® human microRNA array (Applied Biosystems Life Technologies, CA, USA). MiRNAs were analyzed with miRNA TaqMan assays (Applied Biosystems Life Technologies) accordingly to the manufacturer's instruction. Reporters on the microarray cover all mature mouse microRNA sequences as annotated in miRBase v16.0. Sequence Detection System soware (version 2.2; Applied Biosystems Life Technologies) was used to read the expression signals. Each micro-RNA reporter was present four times on the array. Aer hybridization, the microarray slides were washed and scanned with a DNA microarray scanner (Agilent technologies). Feature extraction soware v10 (Agilent technologies) was used to convert the scanned images into TXT les, which were imported in R (http://www.r-project.org/) for further downstream analysis. Ward's method and Manhattan distance interpretation were performed for the cluster analysis.
Ingenuity pathways analysis
To exploring the typical metabolic perturbations associated with the related moleculars, we performed using the IPA system (http://www.ingenuity.com/) which is a web-based soware application that identies biological pathways and functions relevant to bio-molecules of interest. We uploaded the related moleculars onto an IPA server. Canonical pathways and molecular interaction networks were generated based on the IPA knowledge.
Results and discussion
Typical footprint spectra and metabolic changes
Using the optimal chromatography conditions as described, total ion current (TIC) chromatograms of plasma samples for the model group, HXC treatment group and control group were collected in positive and negative modes are shown in Fig. S1 . † TIC proles of typical samples from each group showed in Fig. S1 † displays the general information of UPLC-QTOF/MS detection. Scores plots of PCA indicate the similarity of metabolic proles from various samples. In this study, PCA was rst used to detect any inherent trends within the data. The results showed distinct clustering between the control and model group (Fig. 1A and B) , and indicated that the metabolic proling have been signicantly perturbed in the model group.
Multivariate statistical analysis
To maximize this distinction, the data were analyzed by OPLS-DA to identify potential biomarkers. VIP-plots from the OPLS-DA analysis (Fig. 1C and D) were used to identify which variables account for such a signicant separation. Variables were also generated based on the values of variable importance in the projection (VIP > 6) according to the orders of their contributions to the separation of clustering. Then, by combining Student's t-test with the selected variables, distinct metabolites were identied (p < 0.05) and selected for further study. Based on the VIP plot, 12 endogenous metabolites were selected as biomarkers (Table 1) . Following the identication process, these metabolites were identied over a narrow AE5 ppm, including 7 identied in the positive mode and 5 identied in the negative mode. Furthermore, 7 metabolites were upregulated, and 5 metabolites were downregulated in the model group compared to the control group. Intriguingly, 7 of the metabolites detected were found to be up-regulated, while 5 were down-regulated.
Metabolic pathway analysis
To gain insight into the metabolic mechanism of SS and to provide accurate treatment informations of SS, altered metabolic pathway associated with SS has been further investigated. To determine possible pathways contributing to SS, MetPA analysis was performed to identify metabolic pathways and their networks using an online database. This analysis resulted in the construction of 8 metabolic pathways in the plasma (Fig. S2 † and Table 2 ) that were important for hostresponses to SS. Among the identied metabolic pathways, glycerophospholipid metabolism (impact-value: 0.21) and steroid hormone biosynthesis (impact-value: 0.09), and sphingolipid metabolism (impact-value: 0.03) in plasma were determined to be the most important. This change indicates that SS had signicantly altered metabolism compared to its normal state. Previous study determined that, 28 by using a targeted MS-based quantitative metabolomics approach, glycerophospholipid metabolism was shown to be disturbed in SS disease patients, and relevant endogenous metabolites were detected. These discoveries supported our results regarding metabolism and metabolites. Based on these ndings, we believe that glycerophospholipid metabolism regulation plays an important role in SS disease. Early changes in the plasma levels of these metabolites associated with mortality have potential implications for early intervention.
Metabolic effects of HXC treatment
The PCA score plot was used to investigate the metabolic effects of intervention with the HXC. As shown in Fig. 2A and B, the clusters representing the HXC treatment group was located between the clusters representing the model and control, which demonstrated that the disturbed metabolic states of model group was in the process of returning to the normal state aer HXC treatment (Fig. 2C) . Compared to the model group, the HXC treatment group showed the recovery performance from the model metabolic state. The score plot in the negative mode also showed that the HXC-treated group cluster was closer to that of the control groups than the model group cluster, which a Total is the total number of compounds in the pathway; the hits is the actually matched number from the user uploaded data; the impact is the pathway impact value calculated from pathway topology analysis. demonstrates that HXC has therapeutic effects on SS rats. Ten metabolites were reversed by HXC, and the metabolites that were reversed are primarily involved in glycerophospholipid metabolism and steroid hormone biosynthesis, and sphingolipid metabolism, which indicate that the effectiveness of HXC as an SS treatment depends on modulating metabolism pathways.
miRNA proles aer HXC treatment
We then investigated the HXC inuence on the microRNAome in the SS. PCA scores plot of HXC affecting on SS rats showed patterns of differentially expressed microRNAs abundance among the HXC group and model group (Fig. 3A) . A total of 1547 miRNAs were detected, and of which 56 miRNAs were signi-cantly changed during HXC treatment compared with the untreated group (Fig. 3B) . Our data analysis showed that 36 of the altered miRNAs were upregulated, whereas 20 miRNAs were downregulated aer HXC treatment relative to the model group (Fig. 3C, Table 3 ). Relative expression levels (upregulation in red and downregulation in green) of the differentially expressed miRNAs were shown in Fig. 3D . Clustering analysis showed the clear differentiation patterns of differentially expressed microRNAs abundance among the HXC group and model group. In the network function analysis using IPA soware, the related miRNAs and metabolites tended to gather into an integrated network (Fig. 4) . Our study used plasma metabolomics technology to explore changes in the metabolic regulation in response to experimental SS rats and HXC treatment. In this study, the 12 potential metabolite biomarkers identied suggest that multiple metabolic pathways were disturbed in SS rats. These biomarkers regulated the glycerophospholipid metabolism, steroid hormone biosynthesis, and sphingolipid metabolism, in addition to playing an important role in other metabolic pathways. Based on the results of this study, it can be suggested that SS is treated by HXC via the disrupted pathways. miRNAs have recently been used as potential biomarker for the diagnosis and prognosis of sepsis, and have been validated to be potential sepsis biomarker. Recently, a report from Zheng et al. found that the silencing of miR-195 can improve the survival in sepsis, and the inhibition of miR-195 may represent a new therapeutic approach for sepsis. 29 Another group showed that the upregulation of miR-205-5b is a potential therapeutic target for the treatment of sepsis. 30 A variety of miRNAs such as miR-150, miR15a/16, miR-132, miR-122, and miR-27a as biomarkers, were described in the context of sepsis. [31] [32] [33] [34] [35] [36] Importantly, our results demonstrated differential expression of 36 upregulated and 20 downregulated miRNAs in HXC treatment group compared with SS rats. This study would lead to a further understanding of the HXC regulating SS disease and treatment. We conclude that high-throughput microRNA and metabolome expression proling could aid into the elucidation of the mechanism of SS and the therapeutic mechanism of HXC.
